5-溴-2,3-二氢苯并[B]呋喃-7-硼酸 | 690632-72-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 中文名称: 5-溴-2,3-二氢苯并[B]呋喃-7-硼酸
• 英文名称: (5-bromo-2,3-dihydro-1-benzofuran-7-yl)boronic acid
• 英文别名: 5-bromo-2,3-dihydrobenzo-[b]furan-7-boronic acid；5-bromo-2,3-dihydrobenzo[b]furan-7-boronic acid
• CAS: 690632-72-5
• 化学式: C₈H₈BBrO₃
• 分子量: 242.865
• InChiKey: BSSWVOKZPQTKGW-UHFFFAOYSA-N

物化性质

• 熔点：
  150 °C

计算性质

• 辛醇/水分配系数(LogP)：
  0.06
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

SDS

Name:	5-Bromo-2 3-dihydrobenzo[b]furan-7-boronic acid Material Safety Data Sheet
Synonym:	None Known
CAS:	690632-72-5

Section 1 - Chemical Product MSDS Name:5-Bromo-2 3-dihydrobenzo[b]furan-7-boronic acid Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
690632-72-5	5-Bromo-2,3-dihydrobenzo[b]furan-7-bor	97+	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
Harmful if inhaled. May cause respiratory tract irritation.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions. Provide ventilation. Vacuum or sweep up material and place into a suitable, dry disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 690632-72-5: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: beige
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 150 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H8BBrO3
Molecular Weight: 242.86

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Oxidizing agents, acids, bases.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, hydrogen bromide, borane, bromine, oxides of borane.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 690632-72-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-Bromo-2,3-dihydrobenzo[b]furan-7-boronic Acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 690632-72-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 690632-72-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 690632-72-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴-2,3-二氢苯并[B]呋喃-7-硼酸 、 4-溴吡啶 在 四(三苯基膦)钯 sodium carbonate 作用下， 以 乙二醇二甲醚 、 乙醇 、 水 为溶剂， 反应 2.17h， 以76%的产率得到4-(5-bromo-2,3-dihydro-benzofuran-7-yl)-pyridine
  参考文献：
  名称：

  Indol-3-y-carbonyl-piperidin and piperazin-derivatives

  摘要：

  本发明涉及作为V1a受体拮抗剂的吲哒-3-基甲酰哌啶和哌嗪衍生物，其由以下式I表示：其中残基R1至R3如本文所定义。该发明还涉及含有这种化合物的药物组合物，以及制备这些化合物和组合物的方法。该发明还涉及治疗痛经、高血压、慢性心力衰竭、抗利尿素过度分泌、肝硬化、肾病综合征、强迫症、焦虑和抑郁症的方法。

  公开号：

  US20070027163A1

文献信息

• ALKYNYL ALCOHOLS AND METHODS OF USE
  申请人：Genentech, Inc.

  公开号：US20150057260A1

  公开（公告）日：2015-02-26

  The invention relates to compounds of Formula (0): wherein A 1 -A 8 , R 4 and R 5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

  该发明涉及具有以下结构的化合物（0）：其中A1-A8，R4和R5分别具有如本文所述的含义。 公式（0）的化合物及其药物组成物在治疗观察到NF-kB信号不受欢迎或过度激活的疾病和紊乱中是有用的。
• [EN] ALKYNYL ALCOHOLS AND METHODS OF USE<br/>[FR] ALCOOLS ALCYNYLIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015025026A1

  公开（公告）日：2015-02-26

  The invention relates to compounds of Formula (0): wherein A1-A8, R4 and R5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

  该发明涉及以下式的化合物（0）：其中A1-A8，R4和R5分别具有如本文所述的含义。该式（0）的化合物及其药物组合物在治疗观察到NF-kB信号不良或过度激活的疾病和紊乱中是有用的。
• INDOL-3-Y-CARBONYL-PIPERIDIN AND PIPERAZIN-DERIVATIVES
  申请人：Bissantz Caterina

  公开号：US20120040990A1

  公开（公告）日：2012-02-16

  The present invention relates to indol-3-yl-carbonyl-piperidin and piperazin derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the residues R 1 to R 3 are as defined herein. The invention also relates to pharmaceutical compositions containing such compounds, and methods for preparation of the compounds and compositions. The invention further relates to methods for treating dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders.

  本发明涉及一种作为V1a受体拮抗剂的吲哚-3-基甲酰基哌啶和哌嗪衍生物，其由式I表示：其中残基R1至R3如本文所定义。本发明还涉及含有此类化合物的制药组合物，以及制备该化合物和组合物的方法。本发明还涉及治疗痛经、高血压、慢性心力衰竭、不适当分泌加压素、肝硬化、肾病综合征、强迫症、焦虑和抑郁症的方法。
• Exploring the chemical space of functionalized [1,2,4]triazolo[4,3-a]quinoxaline-based compounds targeting the bromodomain of BRD9
  作者：Erica Gazzillo、Martina Pierri、Ester Colarusso、Maria Giovanna Chini、Maria Grazia Ferraro、Marialuisa Piccolo、Carlo Irace、Ines Bruno、Giuseppe Bifulco、Stefania Terracciano、Gianluigi Lauro

  DOI：10.1016/j.bioorg.2023.106677

  日期：2023.10

  previously introduced by us, were here employed to evaluate a second generation of compounds, exploring different substitution patterns on the heterocyclic core. Starting from the promising data obtained from our previously identified [1,2,4]triazolo[4,3-a]quinoxaline-based compounds 1–4, the combination of in silico studies, chemical synthesis, biophysical and in vitro assays led to the identification

  在这里，我们报告了一项与基于[1,2,4]三唑并[4,3- a ]喹喔啉的化合物相关的详细构效关系（SAR）研究，该化合物针对含溴结构域蛋白9（BRD9）的读取器模块。我们之前引入的基于 3D 结构的药效团模型在这里用于评估第二代化合物，探索杂环核心上的不同取代模式。从我们之前鉴定的[1,2,4]三唑并[4,3- a ]喹喔啉基化合物1 – 4获得的有希望的数据开始，计算机研究、化学合成、生物物理和体外测定的结合导致鉴定了一组新的衍生物，选择这些衍生物是为了彻底探索溴结构域结合位点的化学空间。更详细地说，对 C-4 位置不同接头的研究强调了胺间隔基对于与蛋白质对应物的结合是必需的，以及 C-1 处的烷基取代基对于增加对 BRD9 的选择性的关键作用。此外，从我们收集的结果分析中推断出氢键供体基团的重要性，氢键供体基团对于锚定 ZA 区域至关重要，并且是与 Ile53 残基相互作用所必需的。
• 9<i>H</i>-Purine Scaffold Reveals Induced-Fit Pocket Plasticity of the BRD9 Bromodomain
  作者：Sarah Picaud、Maria Strocchia、Stefania Terracciano、Gianluigi Lauro、Jacqui Mendez、Danette L. Daniels、Raffaele Riccio、Giuseppe Bifulco、Ines Bruno、Panagis Filippakopoulos

  DOI：10.1021/jm501893k

  日期：2015.3.26

  The 2-amine-9H-purine scaffold was identified as a weak bromodomain template and was developed via iterative structure based design into a potent nanomolar ligand for the bromodomain of human BRD9 with small residual micromolar affinity toward the bromodomain of BRD4. Binding of the lead compound 11 to the bromodomain of BRD9 results in an unprecedented rearrangement of residues forming the acetyllysine recognition site, affecting plasticity of the protein in an induced-fit pocket. The compound does not exhibit any cytotoxic effect in HEK293 cells and displaces the BRD9 bromodomain from chromatin in bioluminescence proximity assays without affecting the BRD4/histone complex. The 2-amine-9H-purine scaffold represents a novel template that can be further modified to yield highly potent and selective tool compounds to interrogate the biological role of BRD9 in diverse cellular systems.